Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Ildiko Lingvay MD, MPH, MSCS

Ildiko Lingvay MD, MPH, MSCS

Professor of Medicine, Department of Internal Medicine/ Endocrinology; Professor, Peter O'Donnell Jr. School of Public Health; Medical Director, Office of Clinical Trials Management, University of Texas Southwestern Medical Center, Dallas, Texas

Dr. Ildiko Lingvay is Professor of Medicine in the Division of Endocrinology as well as the Department of Population and Data Sciences at UT Southwestern Medical Center. Dr. Lingvay is the Medical Director of the Office of Clinical Trials Management, overseeing all clinical trials at UT Southwestern.

Dr Lingvay leads a research program that focuses on clinical research in the field of obesity and Type 2 diabetes, with the ultimate goal to improve the lives of all patients who suffer so many health consequences as a result of their medical problems. Her research interests span the spectrum from pathophysiology of the disease to treatment algorithms and comparative effectiveness of various therapeutic approaches. Dr Lingvay sees patients at the UT clinics and hospital as well as the Parkland Health & Hospital System.

Dr Lingvay is an active member of the American Diabetes Association, where she has served on several committees, including the Organizing Committee for the 2017-2019 Annual Scientific Sessions, Focus on Fellows Advisory Board, and most recently the WIN-ADA Advisory Board. She has participated in many clinical trials and has a special interest in cardiovascular trials in diabetes. She authored over 60 publications in major medical journals and authored chapters in several diabetes textbooks.

Disclosures

Dr. Lingvay provides the following disclosures:

  • Research funding (paid to the institution): NovoNordisk, Merck, Novartis, GI Dynamics, Pfizer, Mylan
  • Research Related Consulting (paid to the institution): NovoNordisk
  • Consulting/Advisory Boards: Novo Nordisk, AstraZeneca, Boeringher-Ingelheimer, TARGETPharma, Intarcia, Valeritas, Lilly, Sanofi, Mannkind
  • Other support (travel and/or publication support): NovoNordisk, AstraZeneca, Boeringher-Ingelheimer, Lilly, Sanofi

Current information is publicly available on the UT Southwestern Conflict of Interest site:https://www.utsouthwestern.edu/research/research-administration/conflict-of-interest/public-disclosure.html

Recent Contributions to PracticeUpdate:

  1. Insulin Efsitora vs Degludec in Patients With Type 2 Diabetes Without Previous Insulin Treatment
  2. Re-Evaluating First-Line Therapies for Youth-Onset Type 2 Diabetes
  3. Management of Type 2 Diabetes With the Dual GIP/GLP-1 Receptor Agonist Tirzepatide
  4. Tirzepatide in Type 2 Diabetes With Increased Cardiovascular Risk
  5. AHA Statement on Obesity and CVD
  6. 2019 ADA and EASD Guidelines for the Management of Hyperglycemia in Type 2 Diabetes
  7. Oral Semaglutide vs Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4)

Most Read This Week

Recently Updated